TiumBio
Manufacturing · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
30 Changchang-ro 40beon-gil Sujeong-gu F...Phone Number
+82 316001500Website
www.tiumbio.comRevenue
$7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About TiumBio
TiumBio is a South Korea-based biopharmaceutical company dedicated to the discovery and development of innovative small molecule and biologic medicines. The company is developing clinical and pre-clinical drug candidates in the areas of immuno-oncology, fibrosis, endometriosis/uterine fibroids, and hemophilia. Founded and led by scientists, TiumBio is committed to delivering therapeutic benefits to the patients who suffer from difficult-to-treat diseases with high unmet needs.Explore more
TiumBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TiumBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at TiumBio
Earning: See what the market has to say on TiumBio recently announced quarterly report
Product Launch: Get notified when TiumBio launches new products
Check if TiumBio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once TiumBio has new funding data
Website visits: Recent activity has been detected on your website
Click to see if TiumBio had a recent Job posting/layoffs
TiumBio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if TiumBio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined TiumBio as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
TiumBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TiumBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TiumBio.
TiumBio financials insights
Gather financial insights about TiumBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$29.6M
TiumBio Tech Stack
A closer look at the technologies used by TiumBio
See more technologies
TiumBio News & Media
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company dedicated to developing novel therapies for rare and intractable diseases, today shared the interim Phase II clinical data for its "first-in-class" Tosposertib (TU2218), a duTiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in-class candidate for novel drug approval and global licensing opportunities Multi-Indication Development: Clinical trials are underway for three indications enhancing the asset value-uterine fibroids, endometrioTiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development
Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) in China SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage...TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218
TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) The first patient with head and neck squamous cell carcinoma was dosed in the Phase 2a clinical trial of TU2218 The Phase 2a trial of TU2218 starts with head and neck squamous cell carcinoma, as well as biliary tract cancer patients. It will be later expanded to colorectal cancer patients BOSTON and
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TiumBio
Sign Up For FreeTo access detailed company insights
TiumBio is a South Korea-based biopharmaceutical company dedicated to the discovery and development of innovative small molecule and biologic medicines. The company is developing clinical and pre-clinical drug candidates in the areas of immuno-oncology, fibrosis, endometriosis/uterine fibroids, and hemophilia. Founded and led by scientists, TiumBio... Read More
